Catalog No.
YVV04302
Expression system
E. coli
Species
Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) (LASV)
Protein length
Gly260-Asp432
Predicted molecular weight
22.44 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P08669
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Pre-glycoprotein polyprotein GP complex, Pre-GP-C, Stable signal peptide, SSP, Glycoprotein G1, GP1, Glycoprotein G2, GP2, GPC, GP-C
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816
Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130
The Lassa Virus Stable Signal Peptide Undergoes a Conformational Change to Aid Viral Fusion., PMID:39946735
Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488
Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication., PMID:39339839
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses., PMID:39243373
Cellular N-myristoyl transferases Are Required for Mammarenavirus Multiplication., PMID:39211253
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex., PMID:39013466
Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch., PMID:38851430
Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex., PMID:38370709
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144
Fusogenic structural changes in arenavirus glycoproteins are associated with viroporin activity., PMID:37494374
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies., PMID:37209096
Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion., PMID:37059226
Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation., PMID:36533953
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection., PMID:36400021
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus., PMID:36288283
Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane., PMID:35969633
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever., PMID:35858566
Neutralizing Antibodies against Lassa Virus Lineage I., PMID:35730904
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies., PMID:35613585
Lassa virus glycoprotein complex review: insights into its unique fusion machinery., PMID:35088070
The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion., PMID:34492091
Potent inhibition of arenavirus infection by a novel fusion inhibitor., PMID:34197863
Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response., PMID:33689141
The function annotations of ST3GAL4 in human LAMP1 and Lassa virus GP-C interaction from the perspective of systems virology., PMID:32974605
Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity., PMID:32897505
Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone., PMID:32269122
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene., PMID:32098811
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge., PMID:31466243
Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors., PMID:31456769
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization., PMID:31398326
Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques., PMID:31071008
Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins., PMID:30973897
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067
Structure of the Lassa virus glycan shield provides a model for immunological resistance., PMID:29941589
Lassa virus glycoprotein: stopping a moving target., PMID:29843991
Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses., PMID:29720525
Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development., PMID:29581897
Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments., PMID:29295909
Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins., PMID:29287681
Epistastic Interactions within the Junín Virus Envelope Glycoprotein Complex Provide an Evolutionary Barrier to Reversion in the Live-Attenuated Candid#1 Vaccine., PMID:29070682
Assays to Demonstrate the Roles of Arenaviral Nucleoproteins (NPs) in Viral RNA Synthesis and in Suppressing Type I Interferon., PMID:28986834
Assays to Assess Arenaviral Glycoprotein Function., PMID:28986832
An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions., PMID:28797730
Structural basis for antibody-mediated neutralization of Lassa virus., PMID:28572385
Characterization of the Glycoprotein Stable Signal Peptide in Mediating Pichinde Virus Replication and Virulence., PMID:27630230
Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice., PMID:27581982
Structure-function relationship of the mammarenavirus envelope glycoprotein., PMID:27562602
For research use only. Not for human or drug use.
